Washington, D.C. 20549




Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): November 14, 2005


AVI BioPharma, Inc.

(Exact name of registrant as specified in its charter)







(State or other jurisdiction of




(IRS Employer

incorporation or organization)


File Number)


Identification Number)


One S.W. Columbia, Suite 1105

Portland, OR 97258

(Address of principal executive offices)


(503) 227-0554

Registrant’s telephone number, including area code


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 1.01.                                          Entry into a Material Definitive Agreement


AVI BioPharma, Inc. (Nasdaq: AVII), on November 14, 2005 announced that it had entered into definitive agreements with several  institutional investors for the purchase of  6,941,715 shares of its common stock at $3.26 per share in a direct equity placement for gross proceeds to the company of $22,630,000. The company also entered into a definitive common stock purchase warrant with its placement agent as partial compensation for services rendered in connection with the offering.  The warrants are exercisable for 485,920 shares at $5.00 per share, commencing May 14, 2006 and ending on May 14, 2010. The sale of the 6,941,715 shares of common stock and the issuance of the warrant closed November 14, 2005.


The securities are being sold pursuant to the company’s effective shelf registration statement.


Rodman & Renshaw, Inc., acted as the exclusive placement agent on the transaction. The placement agent will receive a sales commission of 7% of the amount raised, expense reimbursement of $15,000 and a Purchase Warrant equal to 7% of the number of shares sold in the offering up to 485,920 shares.


As part of the transaction the Company entered into a Securities Purchase Agreement and common stock Purchase Warrant containing customary representations and warranties and undertakings regarding the securities issued.


Item 7.    Regulation FD Disclosure


The information set forth above is incorporated by reference herein.


Item 8.    Other Events


The information set forth above is incorporated by reference herein.




Incorporated herein by reference are the following: Purchase Agreement (Exhibit 10.4X). The description of the Purchase Agreement contained herein is qualified in its entirety by the respective terms of the each agreement incorporated herein by reference. A copy of the press release announcing the financing is furnished as Exhibit 99.1 and is incorporated herein by reference.




Note: The information contained in Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.


Item 9. Financial Statements, Pro Forma Financial Information and Exhibits.








Press release dated November 14, 2005 issued by the Company.






Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on November 14, 2005.



AVI BioPharma, Inc.












Alan P. Timmins



President and Chief Operating Officer
(Principal Operating Officer)





Exhibit No.


Document Description






Press release dated November 14, 2005 issued by AVI BioPharma, Inc.